Cephalon Provides Update Related To Final NUVIGIL(TM) Labeling
Fri, 08 Dec 2006 08:00 AM EST
... Cephalon, Inc. (Nasdaq: CEPH) announced today that the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) has informed the company that it is continuing to evaluate the single case of serious rash reported in a SPARLON(TM) (modafinil) Tablets [C-IV] clinical study. [click link for full article] ...
Related Topics
- Food Labeling
- AIDS-Related Cancers
- Food-Related Diseases
- Water-Related Diseases
- Macular Degeneration
- Modafinil
- Lymphoma, AIDS-Related
- AIDS-Related Lymphoma
- Health-Related Quality of Life
- Quality of Life, Health-Related
- Sports Injury
- Sports Injuries
- Pulmonary Fibrosis
- Autoimmune Diseases
- Musculoskeletal Disorders
- Pregnancy-related hypertension
- Water-Related Injuries
- Healthcare-Related Infections
- AIDS-Related Malignancies
- Heat-Related Illness

Not Signed In -


